Drugs / GLS-5700
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02887482 | Aug 2016 → Oct 2017 | Zika virus infectious disease | GeneOne Life Science, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02809443 | Jul 2016 → Nov 2017 | — | GeneOne Life Science, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2017-10-05 | Inovio Pharmaceuticals | Results Inovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine inovio.com ↗
The phase 1 trial of Inovio’s DNA-based Zika vaccine (GLS-5700) induced high levels of binding antibodies in 100% of participants. |
| 2017-06-07 | Inovio Pharmaceuticals | Results Inovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) protected against Zika virus-induced damage to testes and sperm, and prevented persistence of the virus in the reproductive tract of all vaccinated male mice challenged with a high dose of the Zika virus. |
| 2017-02-23 | Inovio Pharmaceuticals | Results Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases inovio.com ↗
Significant immune responses observed in 100% of Zika-vaccinated subjects and 98% of MERS-vaccinated human subjects in separate phase I studies |
| 2016-12-21 | Inovio Pharmaceuticals | Results Inovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase I trial. |
| 2016-11-10 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain Damage and Death inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio and its collaborators have published results in Nature Partner Journals (npj) Vaccines demonstrating that its Zika DNA vaccine (GLS-5700) protected animals from infection, brain damage and death. |
| 2016-06-20 | Inovio Pharmaceuticals | Regulatory Inovio Pharmaceuticals and GeneOne Life Science Receive Approval for First-in-Man Zika Vaccine Clinical Trial inovio.com ↗ |
| 2016-05-16 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals Zika Vaccine Produces Robust Immune Responses in Non-Human Primates inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that testing of its synthetic vaccine for the Zika virus induced robust antibody and T cell responses in non-human primates (monkeys), demonstrating the product’s potential to prevent infection from this harmful pathogen. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLS-5700 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02809443 ↗ |
| Modality | Vaccine | “a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins” PMID 34525286 ↗ Sep 2021 |